<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491825</url>
  </required_header>
  <id_info>
    <org_study_id>CTCL_Classifier_KLIF</org_study_id>
    <nct_id>NCT04491825</nct_id>
  </id_info>
  <brief_title>Diagnostic Classifier for Cutaneous T-cell Lymphomas</brief_title>
  <official_title>Diagnostic Classifier for Cutaneous T-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary cutaneous T-cell lymphomas (CTCL) are a form of skin cancer that is derived from&#xD;
      immune cells. The most common form of CTCL is mycosis fungoides (MF). While initially&#xD;
      confined to the skin, MF may spread to lymph nodes, blood or inner organs, resulting in an&#xD;
      overall poor prognosis for the patient. Thus, being a potentially lethal disease, an early&#xD;
      and correct diagnosis of MF has very important implications for the patient. However,&#xD;
      diagnosis of early MF is often difficult, as it usually shows a close resemblance to benign&#xD;
      inflammatory conditions such as eczema and psoriasis. Strikingly, it takes an average of 3-6&#xD;
      (!) years from the appearance of the first skin lesions until a diagnosis of MF can be made.&#xD;
      For this reason, a test to distinguishing early MF from benign inflammatory conditions is&#xD;
      urgently mandated. By using skin suction blister fluid as well as skin biopsies from patients&#xD;
      with MF, eczema and psoriasis, the investigators want to develop a classifier system that can&#xD;
      distinguish early MF from benign inflammatory skin diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proteomic signature of MF in comparison to eczema, psoriasis, and healthy control skin</measure>
    <time_frame>At baseline</time_frame>
    <description>Proteomic multiplex assay</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>CTCL/ Mycosis Fungoides</condition>
  <arm_group>
    <arm_group_label>Mycosis fungoides (MF)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Eczema (Atopic Dermatitis)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Plaque-Psoriasis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Skin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin suction blistering and skin biopsies</intervention_name>
    <description>Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.</description>
    <arm_group_label>Chronic Plaque-Psoriasis</arm_group_label>
    <arm_group_label>Eczema (Atopic Dermatitis)</arm_group_label>
    <arm_group_label>Healthy Control Skin</arm_group_label>
    <arm_group_label>Mycosis fungoides (MF)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Suction blister fluid and skin biopsies.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MF patients need prior histopathological verification of their disease.&#xD;
&#xD;
        Eczema and psoriasis patients will be diagnosed clinically and, if necessary, on a&#xD;
        histopathological basis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical and/or histopathological diagnosis of MF, eczema or psoriasis&#xD;
&#xD;
          -  Healthy control subjects without personal history of MF, eczema or psoriasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing skin-targeted treatment (Wash out times: 2 weeks for topical, and 4 weeks for&#xD;
             systemic treatments)&#xD;
&#xD;
          -  Ongoing other treatment that might, in the opinion of the investigator, influence&#xD;
             proteomic features of the samples to be acquired&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Patrick M Brunner, MD, MSc</last_name>
    <phone>+43140400</phone>
    <phone_ext>77020</phone_ext>
    <email>patrick.brunner@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Brunner, MD, MSc</last_name>
      <phone>+436644605954</phone>
      <email>patrick.brunner@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Patrick M. Brunner</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

